Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Journal of Radiation Research|June 14, 2021
Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapySatoshi Saito, Takanori Abe, Misaki Iino, et al.
Cancer Immunology Research|December 25, 2019
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 TherapyHiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, et al.
Cancer Medicine|August 20, 2021
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancerHisao Imai, Takayuki Kishikawa, Hiroyuki Minemura, et al.
Nature Communications|March 28, 2026
The CD4+ T cell population partners with Tpex CD8+ T cells to mediate antitumor immunity in the tumor microenvironmentShota Takei, Satoshi Yamasaki, Ou Yamaguchi, et al.
Japanese Journal of Clinical Oncology|June 18, 2020
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in JapanYuichiro Ohe, Terufumi Kato, Fumikazu Sakai, et al.
Cancer Reports (Hoboken, N.J.)|July 28, 2022
Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa-associated lymphoid tissue lymphoma: A case reportAyako Shiono, Hisao Imai, Tsugumi Satou, et al.
Cancer Research|October 11, 2022
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade EfficacyHiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, et al.
Cancer Medicine|August 7, 2021
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumorHisao Imai, Kyoichi Kaira, Kosuke Hashimoto, et al.
Thoracic Cancer|March 12, 2020
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse eventsYu Miura, Atsuto Mouri, Kyoichi Kaira, et al.
Oncology|July 8, 2021
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab MonotherapyHisao Imai, Takayuki Kishikawa, Hiroyuki Minemura, et al.
Pageof 10